LATEST NEWS

Nov-07-2018

Protalix BioTherapeutics Reports 2018 Third Quarter Results and Provides Corporate Update

CARMIEL, Israel, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced its financial results for the three months and nine months ended September 30, 2018, and provided a corporate update. “In the third quarter we achieved two important miles... 
Oct-29-2018

Protalix BioTherapeutics to Hold Third Quarter 2018 Financial Results and Corporate Update Conference Call on November 7, 2018

CARMIEL, Israel, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it will report third quarter 2018 financial results and provide a corporate update on Wednesday, November 7, 2018 at 8:30 am ET. To participate in the conference call... 
Oct-05-2018

Protalix BioTherapeutics Presents Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 1st Canadian Symposium on Lysosomal Diseases 2018

~Preliminary Results Indicate Significant Improvement in Kidney Function in Patients Switched from agalsidase alfa (Replagal®) to pegunigalsidase alfa (PRX-102)~ A deterioration trend in patients’ kidney function on agalsidase alfa (Replagal®) was reversed to an improvement trend when switched to pegunigalsidase alfa (PRX-102)  Presentation with full data to be held at the 1st Canadian Symposium on Lysosomal Diseases 2018 CARMIEL, Israel, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Protalix BioThe... 
All News